How we help you

Patient insights for clinical development

Volv Global accelerates and de-risks clinical development strategies much earlier in the pharma development lifecycle, improving planning robustness and efficiency through better understanding of patients cohorts and diseases.

De-risk clinical
strategy

Identify a cohort more precisely to establish better clinical development strategies much earlier in the development lifecycle.

Find more patients, earlier, and quicker

Understand disease and disease progression to find the right patients at the right point in the patient journey. Identify patient clusters to support trial site selection.

Expand disease
understanding

Elucidate disease heterogeneity and identify novel endpoints to signpost new biomarkers to optimise protocol design.

Overcome data
gaps

Use advance machine learning techniques to overcome issues of unstructured data, data sparsity and bias in data sources.

Clinical development in the face of complexity

The challenge of understanding disease phenomenology

Complexity of Disease Presentation

Variability in phenotypic expression, progression and comorbidities complicates patient stratification and endpoint selection.

Data Sparsity

Rare diseases or subgroups have small patient populations and may lack sufficient data for robust insights.

Bias in Data Sources

Records may over-represent certain populations or healthcare systems, limiting generalisability.

Data Gaps

Lack of longitudinal and complete datasets that capture the full trajectory of disease evolution makes it difficult to model disease progression.

Unstructured Data

Many critical insights are buried in free-text notes, requiring advanced natural language processing (NLP) to extract.

Incomplete Pathophysiological Insights

Limited understanding of disease biology hinders biomarker identification and endpoint selection for clinical trials.

Supporting Clinical Development

Actionable, state-of-the-art solutions for drug development

We find
more
patients

We find undiagnosed and misdiagnosed patients, expanding the pool of patients for clinical trial recruitment.

We detect
diseases at an
earlier stage

We find patients before the development of traditional symptoms, before they are given conventional therapies.

We predict
patient
outcomes

We enable triage of patients according to prognosis of outcomes, e.g., fast progressors, or progressors to more acute symptoms.

We stratify
patient
cohorts

We differentiate and cluster heterogeneous patient cohorts for more accurate definition of trial inclusion and exclusion criteria.

Leading AI/ML methodology to support Clinical Development

Volv Global’s inTrigue technology

inTrigue is a robust resource to optimise trial design and patient recruitment by leveraging its AI/ML-driven analysis of extensive electronic health records, claims data, and other real-world evidence. By detecting subtle biomarkers, phenotypes and other clinical features which characterise patients, sponsors can streamline enrollment and target the most relevant participants. Additionally, inTrigue’s predictive modelling helps refine protocols and endpoints based on anticipated disease progression, ensuring sponsors gather higher-quality data and reduce trial timelines.

Shaping the future today

Our case studies & challenges in clinical development

MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification

- 05/12/2025

Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat

- 20/11/2025

Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification

- 04/11/2025

Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs

- 21/10/2025

Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment

- 15/10/2025

Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study

- 05/09/2025

Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025

- 25/08/2025

Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment

- 21/08/2025

Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors

- 08/07/2025